equiday e 200 mg kapseli, pehmeä
algol oy - oikea-alfa-tocopherolum - kapseli, pehmeä - 200 mg - tokoferoli (e-vitamiini)
daylette 0,02 mg / 3 mg tabletti, kalvopäällysteinen
gedeon richter plc - drospirenone, ethinylestradiol - tabletti, kalvopäällysteinen - 0,02 mg / 3 mg - drospirenoni ja etinyyliestradioli
quviviq
idorsia pharmaceuticals deutschland gmbh - daridorexant hydrochloride - unihäiriöiden ja ylläpidon häiriöt - psyykenlääkkeiden - quviviq is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.
prid alpha 1.55 g depotlääkevalmiste, emättimeen
ceva santÉ animale - progesterone - depotlääkevalmiste, emättimeen - 1.55 g - progesteroni
ajovy
teva gmbh - fremanezumab - migreenihäiriöt - calcitonin gene-related peptide (cgrp) antagonists - ajovy on tarkoitettu käytettäväksi migreenin ennaltaehkäisyyn aikuisilla, joilla on vähintään 4 migreeni päivää kuukaudessa.
itrafungol vet 10 mg/ml oraaliliuos
virbac - itraconazole - oraaliliuos - 10 mg/ml - itrakonatsoli
maitalon cont 0.02 mg / 3 mg tabletti, kalvopäällysteinen
gedeon richter plc - drospirenonum,ethinylestradiolum - tabletti, kalvopäällysteinen - 0.02 mg / 3 mg - drospirenoni ja etinyyliestradioli
clopidogrel acino
acino ag - klopidogreeli - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antitromboottiset aineet - clopidogrel is indicated in adults for the prevention of atherothrombotic events in: , , , patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease, non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa), st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy, patients suffering from acute coronary syndrome. , ,.